author-photo

Nicola Jane Lawrence

Auckland City Hospital
University of Sydney

37

Papers

737

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

2021 The Lancet
Show All
- Source
- Cite
- Save
Citations (94)
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

2021 European Urology
Show All
- Source
- Cite
- Save
Citations (3)
Communicating prognostic information: what do oncologists think patients with incurable cancer should be told?

2020 Internal Medicine Journal
Show All
- Source
- Cite
- Save
Citations (5)
Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib After Nephrectomy for Localised Renal Cell Carcinoma

2020
Show All
- Source
- Cite
- Save
Citations (0)
TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

2019 BJUI
Show All
- Source
- Cite
- Save
Citations (62)
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
CANCER CLINICAL TRIAL DESIGN IN THE ERA OF TARGETED AND IMMUNOLOGICAL THERAPIES

2019
- Nicola Jane Lawrence
Show All
- Source
- Cite
- Save
Citations (0)
LBA53Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

2019 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (406)